Equities research analysts expect Nextgen Healthcare Inc (NASDAQ:NXGN) to post earnings per share (EPS) of $0.21 for the current quarter, according to Zacks Investment Research. Nine analysts have provided estimates for Nextgen Healthcare’s earnings. The lowest EPS estimate is $0.18 and the highest is $0.23. Nextgen Healthcare posted earnings of $0.19 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 10.5%. The business is expected to report its next quarterly earnings results on Tuesday, July 30th.

On average, analysts expect that Nextgen Healthcare will report full-year earnings of $0.90 per share for the current fiscal year, with EPS estimates ranging from $0.89 to $0.91. For the next fiscal year, analysts forecast that the firm will post earnings of $1.03 per share, with EPS estimates ranging from $0.94 to $1.13. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Nextgen Healthcare.

Nextgen Healthcare (NASDAQ:NXGN) last issued its quarterly earnings results on Tuesday, May 28th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.01. Nextgen Healthcare had a return on equity of 11.03% and a net margin of 4.63%. The firm had revenue of $134.80 million during the quarter, compared to analyst estimates of $133.35 million. The business’s revenue for the quarter was down .7% on a year-over-year basis.

Several research firms have recently commented on NXGN. Leerink Swann upgraded Nextgen Healthcare from a “market perform” rating to an “outperform” rating in a report on Thursday, April 25th. Svb Leerink upgraded Nextgen Healthcare from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $19.00 to $22.00 in a report on Thursday, April 25th. TheStreet upgraded BlackRock TCP Capital from a “c+” rating to a “b” rating in a report on Tuesday, May 28th. Dougherty & Co downgraded Nextgen Healthcare from a “buy” rating to a “neutral” rating in a report on Wednesday, May 29th. Finally, Zacks Investment Research downgraded Heritage Insurance from a “hold” rating to a “strong sell” rating in a report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. Nextgen Healthcare presently has a consensus rating of “Hold” and an average target price of $19.50.

In related news, Director Sheldon Razin sold 4,018 shares of the business’s stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $19.06, for a total transaction of $76,583.08. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director George H. Bristol sold 13,873 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $19.25, for a total value of $267,055.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 19,004 shares of company stock worth $364,819. Company insiders own 17.90% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Morgan Stanley bought a new stake in shares of Nextgen Healthcare during the 3rd quarter valued at $2,444,000. Comerica Bank increased its holdings in Nextgen Healthcare by 1.4% during the 4th quarter. Comerica Bank now owns 47,000 shares of the company’s stock valued at $813,000 after purchasing an additional 665 shares during the period. Oregon Public Employees Retirement Fund purchased a new position in Nextgen Healthcare during the 4th quarter valued at about $276,000. First Trust Advisors LP purchased a new position in Nextgen Healthcare during the 4th quarter valued at about $2,158,000. Finally, PNC Financial Services Group Inc. increased its holdings in Nextgen Healthcare by 37.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,387 shares of the company’s stock valued at $36,000 after purchasing an additional 649 shares during the period. Institutional investors own 69.96% of the company’s stock.

Shares of NXGN traded down $0.25 during trading hours on Friday, hitting $19.78. The company had a trading volume of 2,787 shares, compared to its average volume of 265,415. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of 32.48, a P/E/G ratio of 3.49 and a beta of 1.03. The company’s 50 day moving average is $19.31. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 0.03. Nextgen Healthcare has a 52-week low of $13.89 and a 52-week high of $23.73.

About Nextgen Healthcare

NextGen Healthcare, Inc provides software, services, and analytics solutions to medical and dental group practices in the United States. The company's principal products include NextGen Enterprise EHR, which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools.

Read More: Why does the United States have a lingering trade deficit?

Get a free copy of the Zacks research report on Nextgen Healthcare (NXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nextgen Healthcare (NASDAQ:NXGN)

Receive News & Ratings for Nextgen Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nextgen Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.